Company Overview and News

 
Anfield Energy Announces the Appointment of Stephen S. Lunsford to Board of Directors

2018-05-23 globenewswire
VANCOUVER, British Columbia, May 23, 2018 (GLOBE NEWSWIRE) -- Anfield Energy Inc. (TSX.V:AEC) (OTCQB:ANLDF) (FRANKFURT:0AD) (“Anfield” or “the Company”) is pleased to announce that Stephen S. Lunsford has agreed to join the Company’s Board of Directors. Mr. Lunsford has had an extensive career as a geologist in the uranium sector, spanning four decades, with his vast experience generated through his time working with entities such as Cameco Resources, Inc.

 
K2fly wins work with API

2017-10-05 businessnews.com.au
Subiaco-based tech company K2fly has won a contract to provide its services to the manager of the West Pilbara iron ore project for an undisclosed sum.

 
Energy Fuels: Positioned To Lead The American Uranium Renaissance

2016-12-19 seekingalpha
The uranium price hit a 10-year low of $17.75 USD per lbs in these past weeks, which is close to 90% off the 2007 high - the cure for low.

 
ASX debut day for RTOs

2016-11-22 businessnews.com.au
Perth-based companies K2fly, Zelda Therapeutics and Impression Healthcare have wrapped up their first day of trading on the ASX after completing reverse takeovers.

 
K2fly seeks ASX listing

2016-05-16 businessnews.com.au
Listen to podcasts covering breaking news, items of interest and our Success & Leadership Series events. A wide range of topics covered by our well renowned reporters and WA business leaders. Subscribe on iTunes for updates as they happen. Click here for more

 
Power Resources Ltd takes flight to software and technology sector

2016-05-11 proactiveinvestors.com.au
Power Resources Ltd (ASX:PWW) is looking at a transformational change, with the company preparing to reveal an acquisition in the software and technology sector. The ASX has granted the company a trading halt to prepare, with its shares placed in pre-open. The halt will remain in place until the opening of trade on Monday 16th May 2016, or earlier if an announcement is made to the market.

 
Trading Halt

2016-05-11 asx.com.au

 
Appendix 5B

2016-04-29 asx.com.au

 
Quarterly Activities Report

2016-04-29 asx.com.au

 
Appendix 5B

2016-03-31 asx.com.au

 
Half Year Accounts

2016-03-14 asx.com.au

 
Appendix 5B

2016-02-29 asx.com.au

 
Quarterly Activities Report

2016-01-29 asx.com.au

 
Quarterly Cashflow Report

2016-01-29 asx.com.au

 
Appendix 5B

2015-12-22 asx.com.au

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...